Cite

    Vijay Patil et al.. “Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.” Oral oncology, vol. 134, 2022, p. . http://access.bl.uk/ark:/81055/vdc_100167913127.0x000019